During the past decade, Yunnan Cancer Hospital conducted 68 clinical trials. In the 10-year time frame, 68 clinical trials started and 3 clinical trials were completed, i.e. on average, 4.4% percent of trials that started reached the finish line to date. In the past 5 years, 39 clinical trials started and 2 clinical trials were completed. i.e. 5.1% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Yunnan Cancer Hospital" #1 sponsor was "BeiGene" with 9 trials, followed by "Shenzhen Geno-Immune Medical Institute" with 7 trials sponsored, "Chia Tai Tianqing Pharmaceutical Group Co., Ltd." with 4 trials sponsored, "Jiangsu HengRui Medicine Co., Ltd." with 4 trials sponsored and "Shanghai Henlius Biotech" with 4 trials sponsored. Other sponsors include 41 different institutions and companies that sponsored additional 42 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Yunnan Cancer Hospital" #1 collaborator was "Jiangsu Hansoh Pharmaceutical Co., Ltd." with 2 trials as a collaborator, "Yunnan Cancer Hospital" with 2 trials as a collaborator, "Astellas Pharma Inc" with 1 trials as a collaborator, "Australasian Lung Cancer Trials Group" with 1 trials as a collaborator and "BeiGene, Ltd." with 1 trials as a collaborator. Other collaborators include 13 different institutions and companies that were collaborators in the rest 23 trials.

According to Clinical.Site data, the most researched conditions in "Yunnan Cancer Hospital" are "Non-small Cell Lung Cancer" (5 trials), "Breast Cancer" (4 trials), "Breast Neoplasms" (3 trials), "Lung Cancer" (3 trials) and "Non-Small Cell Lung Cancer" (3 trials). Many other conditions were trialed in "Yunnan Cancer Hospital" in a lesser frequency.

Most popular intervention types in "Yunnan Cancer Hospital" are "Drug" (61 trials), "Biological" (13 trials), "Radiation" (4 trials), "Other" (2 trials) and "Combination Product" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (14 trials), "Tislelizumab" (8 trials), "Cisplatin" (5 trials), "Capecitabine" (4 trials) and "Carboplatin" (4 trials). Other intervention names were less common.

The vast majority of trials in "Yunnan Cancer Hospital" are 61 trials for "All" genders, 10 trials for "Female" genders and 3 trials for "Male" genders.

Currently, there are 44 active trials in "Yunnan Cancer Hospital". 2 are not yet recruiting, 23 are recruiting, 18 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 9 completed trials in Yunnan Cancer Hospital, 1 suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Yunnan Cancer Hospital, 14 "Phase 1" clinical trials were conducted, 28 "Phase 2" clinical trials and 38 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 4 trials that are defined as “Not Applicable".